NCT06978088
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06978088
Title LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Zulfa Omer
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.